Compare SPCB & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | ATRA |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 38.9M |
| IPO Year | 2004 | 2014 |
| Metric | SPCB | ATRA |
|---|---|---|
| Price | $10.37 | $10.26 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 65.0K | ★ 109.4K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $3.92 |
| 52 Week High | $13.57 | $19.15 |
| Indicator | SPCB | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 57.07 |
| Support Level | $9.76 | $8.95 |
| Resistance Level | $10.86 | $11.35 |
| Average True Range (ATR) | 0.70 | 0.81 |
| MACD | -0.21 | -0.15 |
| Stochastic Oscillator | 24.19 | 35.00 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).